PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35432205-21	2022	Indeed, in non-obese diabetic mice, treatment with anti-Bcl-2 inhibitors, such as ABT199, eliminates senescent pancreatic beta cells, resulting in prevention of diabetes mellitus.	venetoclax	82-88	B cell leukemia/lymphoma 2	Mus musculus	56-61	
34667127-7	2022	PREVENTION RELEVANCE: This study demonstrates that prophylactic treatment with the BCL2-specific antagonist venetoclax prevents breast cancer initiated by a mutated and activated PIK3CA, the most common breast oncogene.	venetoclax	108-118	B cell leukemia/lymphoma 2	Mus musculus	83-87	
33976278-8	2021	Notably, a head-to-head comparison of Disarib to ABT199, the only FDA approved BCL2 inhibitor revealed that Disarib is as potent as ABT199.	venetoclax	49-55	B cell leukemia/lymphoma 2	Mus musculus	79-83	
32677976-8	2020	Furthermore, DT2216 combined with ABT199 (a selective Bcl-2 inhibitor) synergistically reduced disease burden and improved survival in a TCL PDX mouse model dependent on both Bcl-2 and Bcl-xL.	venetoclax	34-40	B cell leukemia/lymphoma 2	Mus musculus	54-59	
32677976-8	2020	Furthermore, DT2216 combined with ABT199 (a selective Bcl-2 inhibitor) synergistically reduced disease burden and improved survival in a TCL PDX mouse model dependent on both Bcl-2 and Bcl-xL.	venetoclax	34-40	B cell leukemia/lymphoma 2	Mus musculus	175-180	
30017199-10	2018	Given that ABT-199 induces apoptosis in NPC cells through the Bcl-2/Noxa/Mcl-1 axis, treatment avenues further targeting this pathway should be promising.	venetoclax	11-18	B cell leukemia/lymphoma 2	Mus musculus	62-67	
31640928-4	2020	Moreover, Venetoclax, the anti-Bcl-2 drug, and Cirmtuzumab, the monoclonal antibody against ROR1, are synergistic in killing CLL cells.	venetoclax	10-20	B cell leukemia/lymphoma 2	Mus musculus	31-36	
30155839-4	2018	METHODS: The synergistic effect of gemcitabine combined with specific B cell CLL/lymphoma 2 (Bcl-2) inhibitor ABT-199 against pancreatic cancer was tested using cell viability, cell cycle, and apoptosis assays in vitro and in an MIA Paca-2 xenograft model in vivo.	venetoclax	110-117	B cell leukemia/lymphoma 2	Mus musculus	70-91	
30155839-4	2018	METHODS: The synergistic effect of gemcitabine combined with specific B cell CLL/lymphoma 2 (Bcl-2) inhibitor ABT-199 against pancreatic cancer was tested using cell viability, cell cycle, and apoptosis assays in vitro and in an MIA Paca-2 xenograft model in vivo.	venetoclax	110-117	B cell leukemia/lymphoma 2	Mus musculus	93-98	
29666304-5	2018	We demonstrate that DLBCL and MCL cell lines, primary patient samples, and PDX mouse models expressing high BCL-2 levels are extremely sensitive to venetoclax treatment.	venetoclax	148-158	B cell leukemia/lymphoma 2	Mus musculus	108-113	
29944468-9	2018	The Bcl-2 selective inhibitor ABT-199 reduces particulate matter-induced lung inflammation by inducing the apoptosis of neutrophils and might be a promising drug for the treatment of particulate matter-induced lung inflammation.	venetoclax	30-37	B cell leukemia/lymphoma 2	Mus musculus	4-9	
29854301-10	2018	Venetoclax, an inhibitor of BCL-2, showed activity against the transformed cell line in vitro and could be combined with ruxolitinib in vivo.	venetoclax	0-10	B cell leukemia/lymphoma 2	Mus musculus	28-33	
29386360-0	2018	Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma.	venetoclax	44-54	B cell leukemia/lymphoma 2	Mus musculus	85-89	
28663582-7	2018	Cotreatment of ARV-771 with ibrutinib or the BCL2 antagonist venetoclax or CDK4/6 inhibitor palbociclib synergistically induced apoptosis of MCL cells.	venetoclax	61-71	B cell leukemia/lymphoma 2	Mus musculus	45-49	
29386360-4	2018	BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax.	venetoclax	165-175	B cell leukemia/lymphoma 2	Mus musculus	0-4	
29386360-4	2018	BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax.	venetoclax	165-175	B cell leukemia/lymphoma 2	Mus musculus	150-154	
27693384-3	2016	Here, we have investigated the mechanism of Disarib-induced cytotoxicity, and compared its efficacy with a well-established BCL2 inhibitor, ABT199.	venetoclax	140-146	B cell leukemia/lymphoma 2	Mus musculus	124-128	
29118061-3	2018	Venetoclax induced BIM-dependent apoptosis in vitro and blocked tumor growth and induced tumor regressions in mice bearing high BCL-2-expressing SCLC tumors in vivo BCL-2 expression was a predictive biomarker for sensitivity in SCLC cell lines and was highly expressed in a subset of SCLC cell lines and tumors, suggesting that a substantial fraction of patients with SCLC could benefit from venetoclax.	venetoclax	0-10	B cell leukemia/lymphoma 2	Mus musculus	128-133	
29118061-3	2018	Venetoclax induced BIM-dependent apoptosis in vitro and blocked tumor growth and induced tumor regressions in mice bearing high BCL-2-expressing SCLC tumors in vivo BCL-2 expression was a predictive biomarker for sensitivity in SCLC cell lines and was highly expressed in a subset of SCLC cell lines and tumors, suggesting that a substantial fraction of patients with SCLC could benefit from venetoclax.	venetoclax	0-10	B cell leukemia/lymphoma 2	Mus musculus	165-170	
28566329-2	2017	The BCL-2 small-molecule inhibitor venetoclax shows promising clinical response rates in several lymphomas, but is not curative as monotherapy.	venetoclax	35-45	B cell leukemia/lymphoma 2	Mus musculus	4-9	
28915653-3	2017	To this purpose we evaluated 15 targeted drugs in combination with idasanutlin in three p53 wild type neuroblastoma cell lines and identified the BCL2 inhibitor venetoclax (ABT-199) as a promising interaction partner.	venetoclax	161-171	B cell leukemia/lymphoma 2	Mus musculus	146-150	
26254443-8	2015	Cotreatment with BA and panobinostat (pan-histone deacetylase inhibitor) or palbociclib (CDK4/6 inhibitor) or ABT-199 (BCL2 antagonist) synergistically induced apoptosis of the ibrutinib-resistant MCL cells.	venetoclax	110-117	B cell leukemia/lymphoma 2	Mus musculus	119-123	
25880088-3	2015	Recently, ABT-199, a selective BCL-2 antagonist, was developed.	venetoclax	10-17	B cell leukemia/lymphoma 2	Mus musculus	31-36	
27353420-0	2016	Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.	venetoclax	88-98	B cell leukemia/lymphoma 2	Mus musculus	72-77	
27353420-1	2016	BACKGROUND: Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical and clinical studies in acute myeloid leukemia (AML).	venetoclax	12-22	B cell leukemia/lymphoma 2	Mus musculus	95-100